Yevhenii Khil/iStock via Getty Images AtaiBeckley Inc. ( ATAI ) is a clinical-stage company that develops psychedelic therapies for treatment-resistant depression (TRD) and social anxiety disorder (SAD). It was formed after a combination of Atai Life Sciences and Beckley Psytech. ATAI's pipeline includes BPL-003 for TRD, which will enter Phase 3 in Q2 2026 based on the efficacy shown in its recent...
Yevhenii Khil/iStock via Getty Images AtaiBeckley Inc. ( ATAI ) is a clinical-stage company that develops psychedelic therapies for treatment-resistant depression (TRD) and social anxiety disorder (SAD). It was formed after a combination of Atai Life Sciences and Beckley Psytech. ATAI's pipeline includes BPL-003 for TRD, which will enter Phase 3 in Q2 2026 based on the efficacy shown in its recent Phase 2 trials. They found that this antidepressant's effect was rapid and lasted for weeks. ATAI's pipeline also includes VLS-01 for TRD in Phase 2 and EMP-01 for SAD in Phase 2a. Hence, I believe their R&D progress and healthy runway justify a reiterated “Buy” at these levels for long-term investors willing to speculate on therapeutic psychedelics. Psychedelic Bet AtaiBeckley Inc. is a clinical-stage biotech company developing mental health treatments, especially psychedelic-inspired therapies for serious psychiatric conditions. It was founded in 2018 as Atai Life Sciences. The company then changed its name to Atai Beckley N.V in November 2025 after merging with Beckley Psytech. But they later renamed the company again to AtaiBeckley Inc. in December 2025 after it redomiciled from the Netherlands to Delaware. ATAI is now headquartered in New York, NY. I also previously covered ATAI last October, but since then, the stock has declined by about 46.9%, so I thought it was worthwhile updating my thesis on this name. Source: Investor Day Presentation. March 2026. At its core, I believe that ATAI's thesis is that existing treatments may help with symptoms of depression and anxiety. However, the current standard of care often requires frequent dosing over long periods and doesn't lead to lasting benefits. Fortunately, ATAI's drug candidates aim to solve this issue. They are psychedelic-based compounds that may offer a rapid onset, more durable effects, need less frequent dosing, and promote neuroplasticity. Additionally, ATAI argues that psychedelic therapies create benefits th...
BrianAJackson Crypto.com has cut ~12% of its global workforce, or about 180 employees, The Straits Times reported , citing an e-mail sent to affected employees on Thursday morning. The layoffs are a part of the Singapore-based cryptocurrency exchange's reorganization, as part of which it seeks to integrate enterprise-wide AI , the March 19 report said. Growth and customer relationship management d...
BrianAJackson Crypto.com has cut ~12% of its global workforce, or about 180 employees, The Straits Times reported , citing an e-mail sent to affected employees on Thursday morning. The layoffs are a part of the Singapore-based cryptocurrency exchange's reorganization, as part of which it seeks to integrate enterprise-wide AI , the March 19 report said. Growth and customer relationship management departments were reportedly the hardest hit. All affected employees have been notified and are receiving resources to support their transition, according to the Singaporean newspaper. Last month, Crypto.com said it received a conditional approval from the U.S. Office of the Comptroller of the Currency to charter Foris Dax National Trust Bank, doing business as Crypto.com National Trust Bank. More on Crypto S&P 500 to be offered as 24/7 crypto-linked contract SEC approves Nasdaq plan for tokenized stock trading and settlement
Taysha Gene Therapies press release ( TSHA ): FY GAAP EPS of -$0.34 beats by $0.02 . Revenue of $9.77M (+17.3% Y/Y) beats by $3.47M . More on Taysha Gene Therapies Seeking Alpha’s Quant Rating on Taysha Gene Therapies Historical earnings data for Taysha Gene Therapies Financial information for Taysha Gene Therapies
Taysha Gene Therapies press release ( TSHA ): FY GAAP EPS of -$0.34 beats by $0.02 . Revenue of $9.77M (+17.3% Y/Y) beats by $3.47M . More on Taysha Gene Therapies Seeking Alpha’s Quant Rating on Taysha Gene Therapies Historical earnings data for Taysha Gene Therapies Financial information for Taysha Gene Therapies
Building a resilient portfolio means thinking beyond a single asset or market trend. Economic cycles shift, sectors rise and fall, and no one investment performs well in every environment. That's why many investors look to diversify with platforms that provide access to real estate, fixed-income opportunities, professional financial guidance, precious metals, and even self-directed retirement acco...
Building a resilient portfolio means thinking beyond a single asset or market trend. Economic cycles shift, sectors rise and fall, and no one investment performs well in every environment. That's why many investors look to diversify with platforms that provide access to real estate, fixed-income opportunities, professional financial guidance, precious metals, and even self-directed retirement accounts. By spreading exposure across multiple asset classes, it becomes easier to manage risk, capture steady returns, and create long-term wealth that isn't tied to the fortunes of just one company or industry. In 2020, he told CNBC that he had bought some Bitcoin, betting it would be a high-beta gold play. In 2022, however, he said he no longer held the asset, citing quantitative tightening by central banks. Bitcoin surged as much as 800% between 2020 and 2022. Druckenmiller’s long-standing skepticism of the value of cryptocurrencies has, however, not stopped him from speculating on the sector’s volatility and adoption. Druckenmiller said the sector has gained traction, "so it’s going to be a store of value," adding later that "some crypto thing" could replace the U.S. dollar as the global reserve currency. "I said this a long time ago, and I’m going to say it again, [crypto’s] a solution looking for a problem," he told Morgan Stanley. Druckenmiller’s remarks come as stablecoins have ballooned into an over $300 billion sector, with Bank of America (NYSE: BAC ) and Citigroup (NYSE: C ) reportedly among institutions considering their own offerings. Instead of buying someone else's ETF, build an index around your own thesis with Public's AI tools. Get started and see if you qualify for the 1% match. "Blockchain and the use of stablecoins, if you want to throw crypto into that, tokens—incredibly useful in terms of productivity," Druckenmiller said on a recently released interview with Morgan Stanley (NYSE: MS ). "I assume our whole payment systems will be stablecoins in 10 or 1...
(RTTNews) - While reporting financial results for the fourth quarter on Thursday, luxury watch maker Movado Group, Inc. (MOV) said it is not providing financial guidance for the full-year 2027 at this time, given the current economic and geopolitical uncertainty, including the unpredictable impact of the current Middle East conflict and ongoing tariff developments. The Company also announced that ...
(RTTNews) - While reporting financial results for the fourth quarter on Thursday, luxury watch maker Movado Group, Inc. (MOV) said it is not providing financial guidance for the full-year 2027 at this time, given the current economic and geopolitical uncertainty, including the unpredictable impact of the current Middle East conflict and ongoing tariff developments. The Company also announced that the Board of Directors declared the payment on April 16, 2026, of a cash dividend in the amount of $0.35 for each share of the Company's outstanding common stock and class A common stock held by shareholders of record as of the close of business on April 2, 2026. In Thursday's pre-market trading, MOV is trading on the NYSE at $24.00, up $0.95 or 4.12 percent. For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Nucor Corporation (NUE), a maker of steel and related products, said on Thursday that it expects a surge in net profit for the first quarter of 2026, helped by higher average selling prices and volumes. For the three-month period to April 4, the company expects net income of $2.70 to $2.80 per share. For the first quarter of 2025, the steel-maker had reported a net profit of $0.67 per ...
(RTTNews) - Nucor Corporation (NUE), a maker of steel and related products, said on Thursday that it expects a surge in net profit for the first quarter of 2026, helped by higher average selling prices and volumes. For the three-month period to April 4, the company expects net income of $2.70 to $2.80 per share. For the first quarter of 2025, the steel-maker had reported a net profit of $0.67 per share, with adjusted earnings of $0.77 per share. For the fourth quarter of 2025, Nucor had posted net earnings of $1.64 per share, with an adjusted income of $1.73 per share. Nucor, said: "Earnings in the first quarter of 2026 are expected to increase across all three of our operating segments as compared to the fourth quarter of 2025, with the largest increase in the steel mills segment. The expected increase in the steel mills segment earnings is due to higher average selling prices and volumes across all product groups." In the steel products segment, the company anticipates a rise in earnings due to increased volumes and stable average realized pricing. The raw materials segment is also projected to record a slight rise in profit. NUE was down by 0.04% at $161.09 in the pre-market trade on the New York Stock Exchange. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Chair Heather Hallett says pandemic had devastating impact due to NHS being in ‘parlous state’ at time The NHS “teetered on the brink of collapse” during the Covid pandemic, and only just coped thanks to the “superhuman” efforts of healthcare workers, an official inquiry has concluded. In a damning assessment of how the UK’s healthcare systems coped with the pandemic, the Covid-19 inquiry chair, H...
Chair Heather Hallett says pandemic had devastating impact due to NHS being in ‘parlous state’ at time The NHS “teetered on the brink of collapse” during the Covid pandemic, and only just coped thanks to the “superhuman” efforts of healthcare workers, an official inquiry has concluded. In a damning assessment of how the UK’s healthcare systems coped with the pandemic, the Covid-19 inquiry chair, Heather Hallett, said the impact was “devastating” due to the NHS being in a “parlous state” before the outbreak of the virus. The NHS entered the pandemic with low bed numbers, high numbers of staff vacancies and high bed occupancy, meaning it was already in a “precarious position” and ill-prepared to deal with a pandemic. There was not enough PPE at the start of the pandemic, meaning healthcare workers had to put themselves and their families at risk to care for patients. Infection control in the early stages of the pandemic was flawed as it assumed Covid-19 was spread by physical contact, rather than being airborne. The “stay home, protect the NHS, save lives” public message may have inadvertently led to a decline in hospital attendance of life-threatening emergencies such as heart attacks. 80% of healthcare professionals said they acted in a way that conflicted with their values during the pandemic, with some saying they felt they were “playing God” as they were unable to give everyone the treatment they needed. Continue reading...